Bioniche Purchase Will Move Mylan Into Generic Injectables Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Bioniche Pharma will be combined with UDL Laboratories to create new Mylan Institutional unit.
You may also be interested in...
Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff
Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.
Mylan's Acquisition Strategy Now Focuses On "Bolt-Ons"
After three transformative acquisitions, the company aims for 15% CAGR between 2011 and 2013.
Mylan's Acquisition Strategy Now Focuses On "Bolt-Ons"
After three transformative acquisitions, the company aims for 15% CAGR between 2011 and 2013.